A Study of Alisertib (MLN8237) in Adult East Asian Participants With Advanced Solid Tumors or Lymphomas
Status:
Completed
Trial end date:
2013-10-08
Target enrollment:
Participant gender:
Summary
The purpose of this study was to determine the safety profile, maximum tolerated dose (MTD),
recommended Phase 2 dose (RP2D), and to characterize the pharmacokinetic (PK) profile of
alisertib twice daily (BID) dosing for 7 days in East Asian participants with advanced solid
tumors or lymphomas. The secondary objective was to describe any antitumor activity that may
have been observed with alisertib treatment.